Pharma: Clinic Roundup
Tuesday, May 21, 2013
Cempra Inc., of Chapel Hill, N.C., presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin vs. levofloxacin in Cempra's prior Phase II trial in outpatients with community acquired bacterial pneumonia (CABP).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.